Navigation Links
The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project

ST. JOSEPH, Mich., Feb. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.

"GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures," said Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam. "We want to be a part of this innovation to have access to high quality resources to build pathways we need for our research programs that we will use to publish."

"The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka's expertise in this area," said Julie Bryant, GeneGo's VP of Business Development. "This will be the first 'systems analysis' platform devoted specifically for metabolic diseases. We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at

SOURCE GeneGo, Inc.

Back to top



SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Canadian solar photovoltaic research network established; based at McMaster University
2. Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
3. Hahnemann University Hospital Granted Magnet(R) Status
4. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
5. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
6. Nikon Corporation Acquires License From Harvard University For STORM Super Resolution Microscopy -- Will Create Innovative New N-STORM Microscope
7. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
8. iSirona Announces Go-live at University Hospitals in Cleveland
9. Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia
10. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
11. New Program to Bring University of Florida Incubator Companies Millions in New Contracts
Post Your Comments:
(Date:10/12/2015)... ROSEVILLE, Minn. , Oct. 12, 2015 /PRNewswire/ ... Drug Administration (FDA) has designated its lead Microbiota ... for the treatment of recurrent Clostridium difficile ... gastrointestinal (GI) infection that causes 29,000 deaths in ... clinical stage biotechnology company that was founded to ...
(Date:10/12/2015)... , 12 de octubre de 2015 El ... llegó a un récord en el congreso con su ... de la International Plasma Awareness Week (IPAW), que se ... está patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
(Date:10/12/2015)... 2015 offers ... enriched online experience --> ... version for enriched online experience --> ... alternative to print version for enriched online experience ... technical and medical information products and services, announced today ...
Breaking Biology Technology:
(Date:10/12/2015)... India , October 12, 2015 ... a new market research report on the "Digital Security ... technology, & Security Token), by Software (Anti-Phishing, Authentication, Network ... to 2020", published by MarketsandMarkets, the market is expected ... to 2020, and reach USD 14.6 Billion by 2020. ...
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/7/2015)... October 7, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Washington , former long- term executive at American Express ... --> NXTD ) ("NXT-ID" or the "Company"), a ... market and creator of the Wocket® smart wallet announces ...
Breaking Biology News(10 mins):